# US 2024/0002882 A1 · Methods to produce chimeric adeno-associated virus/bocavirus parvovirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002882 A1
- Document ID: US20240002882A1
- Status: Published application
- Kind: A1
- Application number: 18/313,661
- Filed: 2023-05-08
- Published: 2024-01-04
- Earliest claimed: 2016-02-08
- Assignees: University of Iowa Research Foundation; University of Kansas
- Applicants: University of Iowa Research Foundation; University of Kansas
- Inventors: Ziying Yan; John F. Engelhardt; Jianming Qiu
- Web page: https://patentgrep.com/patent/US20240002882A1

## CPC

- C07K 14/005: from viruses
- C12N 15/86: Viral vectors
- C07K 14/015: Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14145: Special targeting system for viral vectors
- C12N 2750/14322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N 2810/6027: ssDNA viruses
- C12N 2830/36: being a transcription termination element
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method of preparing a chimeric virus comprising bocavirus capsid protein (VP) and a recombinant adeno-associated (AAV) viral genome, and isolated mutant bocavirus genomes, are provided.

## Claims

### Claim 1

(canceled)

### Claim 2

A method of preparing a chimeric virus comprising a bocavirus VP1 capsid polypeptide and a recombinant adeno-associated (AAV) viral genome, comprising:
a) isolating the chimeric virus from a host cell that:
(1) expresses the bocavirus VP1 capsid polypeptide, and
(2) does not express one or more of the bocavirus NS1, NS2, NS4 polypeptides, or any combination thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the host cell expresses a bocavirus NS3 polypeptide.

### Claim 4 (depends on 2)

The method of claim 2, wherein the host cell does not express a functional bocavirus NP1 polypeptide.

### Claim 5 (depends on 2)

The method of claim 2, wherein the host cell is a mammalian cell.

### Claim 6 (depends on 2)

The method of claim 2, wherein the host cell is an insect cell.

### Claim 7 (depends on 2)

The method of claim 2, wherein the host cell comprises a rAAV genome.

### Claim 8 (depends on 7)

The method of claim 7, wherein the rAAV genome does not express the functional bocavirus NP1 polypeptide in trans.

### Claim 9 (depends on 2)

The method of claim 2, wherein the host cell does not express one or more of NS1, NS2, NS4 polypeptides, or any combination thereof.

### Claim 10 (depends on 2)

The method of claim 2, wherein the host cell expresses a bocavirus VP2 capsid polypeptide, a bocavirus VP3 capsid polypeptide, or a combination thereof.

### Claim 11 (depends on 2)

The method of claim 2, wherein the rAAV vector comprises an expression cassette encoding a heterologous gene product.

### Claim 12 (depends on 11)

The method of claim 11, wherein the gene product encodes a therapeutic protein.

### Claim 13 (depends on 2)

The method of claim 2, wherein the rAAV genome is a rAAV-2 genome.

### Claim 14 (depends on 2)

The method of claim 2, wherein the gene product is cystic fibrosis transmembrane conductance regulator, b-globin, g-globin, tyrosine hydroxylase, glucocerebrosidase, aryl sulfatase A, factor VIII, dystrophin, alpha 1-antitrypsin, surfactant protein SP-D, SP-A or SP-C, C1 inhibitor gene, C1-INH gene, SERPING gene erythropoietin, HBoV protein, influenza virus protein, RSV protein, a neutralizing antibody or an antigen binding fragment thereof, SARS virus protein, or a cytokine.

### Claim 15 (depends on 2)

The method of claim 2, wherein the bocavirus is a human bocavirus.

### Claim 16 (depends on 2)

The method of claim 2, wherein the method is independent of bocavirus NP1.

### Claim 17 (depends on 16)

The method of claim 16, wherein the bocavirus VP1 capsid polypeptide is encoded by a nucleic acid sequence comprising a silent mutation in one or more polyadenylation signals, relative to a wild type polyadenylation signal.

### Claim 18 (depends on 2)

The method of claim 2, wherein one or more of the following is stably integrated into a genome of the host cell: (1) a coding sequence encoding the bocavirus VP1 capsid polypeptide, (2) a coding sequence encoding a bocavirus NS3 polypeptide, and (3) the recombinant adeno-associated (AAV) viral genome.

### Claim 19 (depends on 2)

The method of claim 2, wherein one or more of the following is not stably integrated into a genome of the host cell: (1) a coding sequence encoding the bocavirus VP1 capsid polypeptide, (2) a coding sequence encoding a bocavirus NS3 polypeptide, and (3) the recombinant adeno-associated (AAV) viral genome.

### Claim 20 (depends on 2)

The method of claim 2, wherein none of the following are stably integrated into a genome of the host cell: (1) a coding sequence encoding the bocavirus VP1 capsid polypeptide, (2) a coding sequence encoding a bocavirus NS3 polypeptide, and (3) the recombinant adeno-associated (AAV) viral genome.

### Claim 21

A host cell comprising a chimeric virus, the chimeric virus comprising a bocavirus VP1 capsid polypeptide and a recombinant adeno-associated (AAV) viral genome,
wherein the host cell (1) expresses the bocavirus VP1 capsid polypeptide; and (2) does not express one or more of the bocavirus NS1, NS2, NS4 polypeptides, or any combination thereof.

### Claim 22 (depends on 21)

The host cell of claim 21, wherein the host cell expresses a bocavirus NS3 polypeptide.

### Claim 23 (depends on 21)

The host cell of claim 21, wherein the host cell is a mammalian cell.

### Claim 24 (depends on 21)

The host cell of claim 21, wherein the host cell is an insect cell.

### Claim 25 (depends on 21)

The host cell of claim 21, wherein one or more of the following is stably integrated into a genome of the host cell: (1) a coding sequence encoding the bocavirus VP1 capsid polypeptide, (2) a coding sequence encoding a bocavirus NS3 polypeptide, and (3) the recombinant adeno-associated (AAV) viral genome.

### Claim 26 (depends on 21)

The host cell of claim 21, wherein one or more of the following is not stably integrated into a genome of the host cell: (1) a coding sequence encoding the bocavirus VP1 capsid polypeptide, (2) a coding sequence encoding a bocavirus NS3 polypeptide, and (3) the recombinant adeno-associated (AAV) viral genome.

### Claim 27 (depends on 21)

The host cell of claim 21, wherein none of the following are stably integrated into a genome of the host cell: (1) a coding sequence encoding the bocavirus VP1 capsid polypeptide, (2) a coding sequence encoding a bocavirus NS3 polypeptide, and (3) the recombinant adeno-associated (AAV) viral genome.

### Claim 28

A population of chimeric viruses, the population comprising a bocavirus VP1 capsid polypeptide and a recombinant adeno-associated (AAV) viral genome,
wherein the population was isolated from a host cell capable of expressing the bocavirus VP1 capsid polypeptide; and
wherein the host cell does not express one or more of bocavirus NS1, NS2, NS4 polypeptides, or any combination thereof.

### Claim 29 (depends on 28)

The host cell of claim 28, wherein the host cell expresses a bocavirus NS3 polypeptide.

### Claim 30 (depends on 28)

The population of claim 28, wherein the host cell is a mammalian cell.

### Claim 31 (depends on 28)

The population of claim 28, wherein the host cell is an insect cell.

### Claim 32 (depends on 28)

The population of claim 28, wherein one or more of the following is stably integrated into a genome of the host cell: (1) a coding sequence encoding the bocavirus VP1 capsid polypeptide, (2) a coding sequence encoding a bocavirus NS3 polypeptide, and (3) the recombinant adeno-associated (AAV) viral genome.

### Claim 33 (depends on 28)

The population of claim 28, wherein one or more of the following is not stably integrated into a genome of the host cell: (1) a coding sequence encoding the bocavirus VP1 capsid polypeptide, (2) a coding sequence encoding a bocavirus NS3 polypeptide, and (3) the recombinant adeno-associated (AAV) viral genome.

### Claim 34 (depends on 28)

The population of claim 28, wherein none of the following are stably integrated into a genome of the host cell: (1) a coding sequence encoding the bocavirus VP1 capsid polypeptide, (2) a coding sequence encoding a bocavirus NS3 polypeptide, and (3) the recombinant adeno-associated (AAV) viral genome.

### Claim 35

A preparation comprising a chimeric virus, the chimeric virus comprising a bocavirus VP1 capsid polypeptide and a recombinant adeno-associated (AAV) viral genome,
wherein the chimeric virus was produced by a host cell capable of expressing the bocavirus VP1 capsid polypeptide; and
wherein the host cell does not express one or more of bocavirus NS1, NS2, NS4 polypeptides, or any combination thereof.

### Claim 36 (depends on 35)

The preparation of claim 35, wherein the host cell expresses a bocavirus NS3 polypeptide.

### Claim 37 (depends on 35)

The population of claim 35, wherein the host cell is a mammalian cell.

### Claim 38 (depends on 37)

The population of claim 37, wherein the host cell is an insect cell.

### Claim 39

A method of treatment comprising:
administering to a subject a chimeric virus comprising a bocavirus VP1 capsid polypeptide and a recombinant adeno-associated (AAV) viral genome,
wherein the chimeric virus was isolated from a host cell that expresses the bocavirus VP1 capsid polypeptide; and
wherein the host cell does not express one or more of bocavirus NS1, NS2, NS4 polypeptides, or any combination thereof.

### Claim 40 (depends on 39)

The method of claim 39, wherein the host cell expresses a bocavirus NS3 polypeptide.

### Claim 41

A method of preparing a chimeric virus comprising bocavirus capsid protein and a recombinant adeno-associated (AAV) viral genome which method is independent of bocavirus NP1, comprising:
a) providing a bocavirus genome vector that when introduced to mammalian cells
i) express bocavirus NS3 and NS4 but not NS1 and NS2,
ii) expresses bocavirus capsid proteins VP1, VP2 and VP3, and
iii) does not express a functional bocavirus NP1,
wherein the coding region for the one or more of the VP1, VP2 or VP3 in the bocavirus genome vector is codon optimized;
b) introducing the bocavirus genome vector and a rAAV vector having an AAV genome into mammalian cells that do not express bocavirus NP1 in trans,
thereby producing bocavirus nonstructural proteins NS3 and NS4, bocavirus capsid proteins and a rAAV genome; and
c) collecting chimeric rAAV/bocavirus virus.
